<DOC>
	<DOCNO>NCT00810485</DOCNO>
	<brief_summary>The purpose study evaluate effect ADX10059 patient gastroesophageal reflux disease partial responder proton pump inhibitor</brief_summary>
	<brief_title>ADX10059 add-on Therapy Proton Pump Inhibitors ( PPIs ) Patients With Gastroesophageal Reflux ( GERD )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>diagnosis typical GERD partial responder stable standard clinical symptom control dose PPI therapy body mass index â‰¤ 32 kg/m2 exclusively atypical symptom GERD symptom show associated GERD erosive oesophagitis treat dose PPI great dose indicate clinical symptom control GERD hiatus hernia &gt; 3 cm current diagnosis coexist psychiatric disease know clinical significant allergy know hypersensitivity drug pregnant breastfeed received sodium valproate topiramate within 30 day Screening history significant medical condition may affect safety patient preclude adequate participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Gastroesophageal reflux</keyword>
	<keyword>Proton pump inhibitor</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Regurgitation</keyword>
</DOC>